Funder
Fujian Collaborative Innovation Center for Research and Development of Coach and Special Vehicle
Takeda Pharmaceuticals North America
Wellcome
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute for Social Care and Health Research
Intercept Pharmaceuticals
Reference36 articles.
1. The global burden of metabolic disease: Data from 2000 to 2019;Chew;Cell Metab,2023
2. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis;Younossi;J Hepatol,2019
3. Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies;Le;Clin Gastroenterol Hepatol,2022
4. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study;Huang;Gastroenterology,2023
5. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD;Gidener;Hepatology,2023